Table of Contents Author Guidelines Submit a Manuscript
HPB Surgery
Volume 2012, Article ID 154056, 8 pages
http://dx.doi.org/10.1155/2012/154056
Review Article

Contemporary Strategies in the Management of Hepatocellular Carcinoma

Institute of Liver Studies, King’s College Hospital, Denmark Hill, London SE5 9RS, UK

Received 12 July 2012; Accepted 17 September 2012

Academic Editor: Andrea Lauterio

Copyright © 2012 Shirin Elizabeth Khorsandi and Nigel Heaton. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. B. El-Serag and A. C. Mason, “Rising incidence of hepatocellular carcinoma in the United States,” The New England Journal of Medicine, vol. 340, no. 10, pp. 745–750, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, supplement 1, pp. S5–S16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Samuel, M. Colombo, H. El-Serag, R. Sobesky, and N. Heaton, “Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma,” Liver Transplantation, vol. 17, supplement 2, pp. S6–S13, 2011. View at Google Scholar
  5. V. Santi, F. Trevisani, A. Gramenzi et al., “Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival,” Journal of Hepatology, vol. 53, no. 2, pp. 291–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Llovet, J. Fuster, and J. Bruix, “Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation,” Hepatology, vol. 30, no. 6, pp. 1434–1440, 1999. View at Google Scholar · View at Scopus
  7. D. Franco, L. Capussotti, C. Smadja et al., “Resection of hepatocellular carcinomas. Reults in 72 European patients with cirrhosis,” Gastroenterology, vol. 98, no. 3, pp. 733–738, 1990. View at Google Scholar · View at Scopus
  8. S. Okada, K. Shimada, J. Yamamoto et al., “Predictive factors for postoperative recurrence of hepatocellular carcinoma,” Gastroenterology, vol. 106, no. 6, pp. 1618–1624, 1994. View at Google Scholar · View at Scopus
  9. M. Minagawa, M. Makuuchi, T. Takayama, and N. Kokudo, “Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma,” Annals of Surgery, vol. 238, no. 5, pp. 703–710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. T. P. Poon, S. T. Fan, C. M. Lo, C. L. Liu, and J. Wong, “Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors,” Annals of Surgery, vol. 229, no. 2, pp. 216–222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. J. G. O'Grady, R. J. Polson, K. Rolles, R. Y. Calne, and R. Williams, “Liver transplantation for malignant disease,” Annals of Surgery, vol. 207, no. 4, pp. 373–379, 1988. View at Google Scholar · View at Scopus
  12. B. Ringe, R. Pichlmayr, C. Wittekind, and G. Tusch, “Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients,” World Journal of Surgery, vol. 15, no. 2, pp. 270–285, 1991. View at Google Scholar · View at Scopus
  13. P. Moreno, E. Jaurrieta, J. Figueras et al., “Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma?” Transplantation Proceedings, vol. 27, no. 4, pp. 2296–2298, 1995. View at Google Scholar · View at Scopus
  14. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” The New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. K. M. Olthoff, A. Forner, S. Hübscher, and J. Fung, “What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?” Liver Transplantation, vol. 17, supplement 2, pp. S26–S33, 2011. View at Google Scholar
  16. F. Y. Yao, L. Ferrell, N. M. Bass et al., “Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival,” Hepatology, vol. 33, no. 6, pp. 1394–1403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Mazzaferro, J. M. Llovet, R. Miceli et al., “Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis,” The Lancet Oncology, vol. 10, no. 1, pp. 35–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Roayaie, J. S. Frischer, S. H. Emre et al., “Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters,” Annals of Surgery, vol. 235, no. 4, pp. 533–539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. N. M. Kneteman, J. Oberholzer, M. Al Saghier et al., “Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma,” Liver Transplantation, vol. 10, no. 10, pp. 1301–1311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. P. E. Majno, F. P. Sarasin, G. Mentha, and A. Hadengue, “Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis,” Hepatology, vol. 31, no. 4, pp. 899–906, 2000. View at Google Scholar · View at Scopus
  21. D. Fuks, S. Dokmak, V. Paradis, M. Diouf, F. Durand, and J. Belghiti, “Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis,” Hepatology, vol. 55, no. 1, pp. 132–140, 2012. View at Google Scholar
  22. R. Adam, D. Azoulay, D. Castaing et al., “Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?” Annals of Surgery, vol. 238, no. 4, pp. 508–519, 2003. View at Google Scholar · View at Scopus
  23. P. E. Majno, R. Adam, H. Bismuth et al., “Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis,” Annals of Surgery, vol. 226, no. 6, pp. 688–703, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. I. W. Graziadei, H. Sandmueller, P. Waldenberger et al., “Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome,” Liver Transplantation, vol. 9, no. 6, pp. 557–563, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Y. Yao, S. Breitenstein, C. E. Broelsch et al., “Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?” Liver Transplantation, vol. 17, supplement 2, pp. S109–S116, 2011. View at Google Scholar
  26. O. Barakat, R. P. Wood, C. F. Ozaki et al., “Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis,” Liver Transplantation, vol. 16, no. 3, pp. 289–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Y. Yao, R. K. Kerlan Jr., R. Hirose et al., “Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis,” Hepatology, vol. 48, no. 3, pp. 819–827, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Y. Lau and E. C. H. Lai, “Salvage surgery following downstaging of unresectable hepatocellular carcinoma—a strategy to increase resectability,” Annals of Surgical Oncology, vol. 14, no. 12, pp. 3301–3309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Ravaioli, G. L. Grazi, F. Piscaglia et al., “Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria,” American Journal of Transplantation, vol. 8, no. 12, pp. 2547–2557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. J. Lewandowski, L. M. Kulik, A. Riaz et al., “A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization,” American Journal of Transplantation, vol. 9, no. 8, pp. 1920–1928, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Kulik and M. Abecassis, “Living donor liver transplantation for hepatocellular carcinoma,” Gastroenterology, vol. 127, supplement 1, pp. S277–S282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Di Sandro, A. O. Slim, A. Giacomoni et al., “Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation,” Transplantation Proceedings, vol. 41, no. 4, pp. 1283–1285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Vakili, J. J. Pomposelli, Y. L. Cheah et al., “Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival,” Liver Transplantation, vol. 15, no. 12, pp. 1861–1866, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. S. Mangus, J. A. Fridell, R. M. Vianna, A. B. Cooper, D. T. Jones, and A. J. Tector, “Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma,” Transplantation, vol. 85, no. 10, pp. 1496–1499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. P. A. Clavien, M. Lesurtel, P. M. Bossuyt et al., “Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report,” The Lancet Oncology, vol. 13, pp. e11–e22, 2012. View at Google Scholar
  36. P. Bhangui, E. Vibert, P. Majno et al., “Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation,” Hepatology, vol. 53, no. 5, pp. 1570–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Chen, K. Huang, J. Wu et al., “Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis,” Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1626–1633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. R. T. P. Poon, S. T. Fan, C. M. Lo et al., “Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?” Annals of Surgery, vol. 236, no. 5, pp. 602–611, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Imamura, Y. Matsuyama, E. Tanaka et al., “Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy,” Journal of Hepatology, vol. 38, no. 2, pp. 200–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Samuel, P. K. Chow, E. Chan Shih-Yen, D. Machin, and K. C. Soo, “Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma,” Cochrane Database of Systematic Reviews, no. 1, article CD001199, 2009. View at Google Scholar · View at Scopus
  41. A. Abulkhir, P. Limongelli, A. J. Healey et al., “Preoperative portal vein embolization for major liver resection: a meta-analysis,” Annals of Surgery, vol. 247, no. 1, pp. 49–57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. K. P. Croome and M. H. Yamashita, “Laparoscopic vs open hepatic resection for benign and malignant tumors: an updated meta-analysis,” Archives of Surgery, vol. 145, no. 11, pp. 1109–1118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Livraghi, F. Meloni, M. Di Stasi et al., “Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?” Hepatology, vol. 47, no. 1, pp. 82–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. K. Cho, J. K. Kim, M. Y. Kim, H. Rhim, and J. K. Han, “Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies,” Hepatology, vol. 49, no. 2, pp. 453–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Lencioni, “Loco-regional treatment of hepatocellular carcinoma,” Hepatology, vol. 52, no. 2, pp. 762–773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Tanaka, M. Shimada, K. Shirabe et al., “Surgical radiofrequency ablation for treatment of hepatocellular carcinoma: an endoscopic or open approach,” Hepato-Gastroenterology, vol. 56, no. 93, pp. 1169–1173, 2009. View at Google Scholar · View at Scopus
  47. F. Di Benedetto, G. Tarantino, R. Montalti et al., “Laparoscopic radiofrequency ablation in the caudate lobe for hepatocellular carcinoma before liver transplantation,” Journal of Laparoendoscopic & Advanced Surgical Techniques, vol. 22, no. 4, pp. 400–402, 2012. View at Publisher · View at Google Scholar
  48. Y. K. Cho, J. K. Kim, W. T. Kim, and J. W. Chung, “Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a markov model analysis,” Hepatology, vol. 51, no. 4, pp. 1284–1290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. S. Chen, J. Q. Li, Y. Zheng et al., “A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma,” Annals of Surgery, vol. 243, no. 3, pp. 321–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Cammà, V. Di Marco, A. Orlando et al., “Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study,” Journal of Hepatology, vol. 42, no. 4, pp. 535–540, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Tateishi, S. Shiina, T. Teratani et al., “Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases,” Cancer, vol. 103, no. 6, pp. 1201–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Huang, L. Yan, Z. Cheng et al., “A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria,” Annals of Surgery, vol. 252, no. 6, pp. 903–912, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Morimoto, K. Numata, M. Kondou, A. Nozaki, S. Morita, and K. Tanaka, “Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization,” Cancer, vol. 116, no. 23, pp. 5452–5460, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Veltri, P. Moretto, A. Doriguzzi, E. Pagano, G. Carrara, and G. Gandini, “Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC),” European Radiology, vol. 16, no. 3, pp. 661–669, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Forner, C. Ayuso, M. Varela et al., “Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?” Cancer, vol. 115, no. 3, pp. 616–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Llovet and J. Bruix, “Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival,” Hepatology, vol. 37, no. 2, pp. 429–442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. J. L. Raoul, B. Sangro, A. Forner et al., “Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization,” Cancer Treatment Reviews, vol. 37, no. 3, pp. 212–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Varela, M. I. Real, M. Burrel et al., “Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics,” Journal of Hepatology, vol. 46, no. 3, pp. 474–481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Lammer, K. Malagari, T. Vogl et al., “Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION v study,” CardioVascular and Interventional Radiology, vol. 33, no. 1, pp. 41–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Craxì, and C. Cammá, “A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma,” Hepatology, vol. 51, no. 4, pp. 1274–1283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Luo, R. P. Guo, E. C. H. Lai et al., “Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study,” Annals of Surgical Oncology, vol. 18, no. 2, pp. 413–420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. L. M. Kulik, B. I. Carr, M. F. Mulcahy et al., “Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis,” Hepatology, vol. 47, no. 1, pp. 71–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. L. M. Kulik, B. Atassi, L. van Holsbeeck et al., “Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation,” Journal of Surgical Oncology, vol. 94, no. 7, pp. 572–586, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. B. Sangro, M. Iñarrairaegui, and J. I. Bilbao, “Radioembolization for hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 2, pp. 464–473, 2012. View at Google Scholar
  65. R. Salem, R. J. Lewandowski, L. Kulik et al., “Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma,” Gastroenterology, vol. 140, no. 2, pp. 497–507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. J. K. Kang, M. S. Kim, C. K. Cho et al., “Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization,” Cancer, vol. 118, no. 21, pp. 5424–5431, 2012. View at Publisher · View at Google Scholar
  67. A. Takeda, M. Takahashi, E. Kunieda et al., “Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity,” Hepatology Research, vol. 38, no. 1, pp. 60–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. R. V. Tse, M. Hawkins, G. Lockwood et al., “Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 657–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. J. H. Kwon, S. H. Bae, J. Y. Kim et al., “Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer,” BMC Cancer, vol. 10, article 475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, “The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide,” Journal of Hepatology, vol. 45, no. 4, pp. 529–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. H. I. Yang, S. N. Lu, Y. F. Liaw et al., “Hepatitis B e antigen and the risk of hepatocellular carcinoma,” The New England Journal of Medicine, vol. 347, pp. 168–174, 2002. View at Google Scholar
  72. H. L. Y. Chan, C. H. Tse, F. Mo et al., “High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 177–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. F. Liaw, J. J. Sung, W. C. Chow et al., “Lamivudine for patients with chronic hepatitis B and advanced liver disease,” The New England Journal of Medicine, vol. 351, pp. 1521–1531, 2004. View at Google Scholar
  74. J. S. W. Wong, G. L. H. Wong, K. K. F. Tsoi et al., “Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 10, pp. 1104–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Raimondi, S. Bruno, M. U. Mondelli, and P. Maisonneuve, “Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis,” Journal of Hepatology, vol. 50, no. 6, pp. 1142–1154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. L. T. Chen, M. F. Chen, L. A. Li et al., “Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection,” Annals of Surgery, vol. 255, no. 1, pp. 8–17, 2012. View at Google Scholar
  77. F. Sahin, R. Kannangai, O. Adegbola, J. Wang, G. Su, and M. Torbenson, “mTOR and P70 S6 kinase expression in primary liver neoplasms,” Clinical Cancer Research, vol. 10, no. 24, pp. 8421–8425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Valdivieso, J. Bustamante, M. Gastaca et al., “Management of hepatocellular carcinoma recurrence after liver transplantation,” Transplantation Proceedings, vol. 42, no. 2, pp. 660–662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. J. M. Alamo, L. Barrera, M. D. Casado et al., “Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation,” Transplantation Proceedings, vol. 41, no. 6, pp. 2181–2183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Vivarelli, A. Dazzi, M. Zanello et al., “Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma,” Transplantation, vol. 89, no. 2, pp. 227–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Söderdahl, L. Bäckman, H. Isoniemi et al., “A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma,” Transplant International, vol. 19, no. 4, pp. 288–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Pokorny, M. Gnant, S. Rasoul-Rockenschaub et al., “Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?” American Journal of Transplantation, vol. 5, no. 4, pp. 788–794, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Google Scholar
  85. R. Kim, G. El-Gazzaz, A. Tan et al., “Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation,” Oncology, vol. 79, no. 1-2, pp. 62–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Yeganeh, R. S. Finn, and S. Saab, “Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib,” American Journal of Transplantation, vol. 9, no. 12, pp. 2851–2854, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Villanueva and J. M. Llovet, “Targeted therapies for hepatocellular carcinoma,” Gastroenterology, vol. 140, no. 5, pp. 1410–1426, 2011. View at Publisher · View at Google Scholar · View at Scopus